Table 1.
Characteristics of the Four Patients
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
|---|---|---|---|---|
| Diagnosis | NHL (DLBCL) IV-B | ALL | NHL (DLBCL) IV-A | NHL (Burkitt L.) IV-B |
| Age (years) | 37 | 45 | 44 | 34 |
| Status at transplant | Chemosensitive relapse | First complete remission | Partial remission | Second complete remission |
| CD4+ HIV-VL at transplant | 54 (cells/μl) <50 copies/ml |
39 (cells/μl) <50 copies/ml |
77 (cells/μl) <50 copies/ml |
73 (cells/μl) 65 copies/ml |
| cART | 3TC, d4T, EFV, NFV | T20, d4T, ABC, 3TC | ddI, T20, 3TC | ABC, 3TC, raltegravir |
| Donor type | Sibling matched | Sibling matched | Sibling matched | Cord blood cell+mismatched third party-related donor |
| Conditioning treatment | MAC TBI+Cy | MAC TBI+Cy | RIC 90YIT+Ritx+Flu+Melf | MAC Flu+Cy+Bu |
| GVHD prophylaxis | CsA | CsA+Mtx | CsA+Mtx | CsA+steroids |
| Neutrophil engraftment, day (d) | Not reached | +17 d | +13 d | +15 d |
| Platelet engraftment, day (d) | Not reached | +14 d | +18 d | +31 d |
| Full donor chimaerism, day (d) | Not reached | +26 d | +32 d | +30 d |
| Acute GVHD grade | NA | III | II | No |
| Chronic GVHD | NA | Extensive | Extensive | No |
| LFU | 6 days | 36 months | 40 months | 9 months |
| Status at LFU | Dead | Dead | Dead | Alive |
ALL, acute lymphoblastic leukemia; cART, combined antiretroviral therapy; CsA, cyclosporine A; DLBCL, diffuse large B cell lymphoma; engraftment day (d) neutrophil >0.5×109/liter and platelets count >20×109/liter; Flu+Cy+Bu, fludarabine, cyclophosphamide, and IV busulfan; GVHD, graft-versus-host disease; HSCT, hematopoietic stem cell transplantation; HIV-VL, HIV viral load; LFU, last follow-up; MAC, myeloablative conditioning; Mtx, methotrexate; NA, not applicable; NHL, non-Hodgkin's lymphoma; RIC, reduced intensity conditioning; TBI, total body irradiation; Cy, cyclophosphamide; 90YIT+Ritx+Flu+Melf, 90Y-ibritumomab-tiuxetan, rituximab, fludarabine, and melphalan; 3TC, lamivudine; d4T, stavudine; EFV, efavirenz; NFV, nelfinavir; T20, enfuvirtide; ABC, abacavir; ddI, didanosine.